These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24320787)

  • 1. Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study.
    Karlsson J; Söderström A; Augustini BG; Berggren AC
    Curr Med Res Opin; 2014 Apr; 30(4):575-87. PubMed ID: 24320787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.
    Karlsson M; Berggren AC
    Clin Ther; 2009 Mar; 31(3):503-13. PubMed ID: 19393841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
    Yoon DH; Bin SI; Chan SK; Chung CK; In Y; Kim H; Lichauco JJ; Mok CC; Moon YW; Ng TK; Penserga EG; Shin DA; You D; Moon H
    BMC Musculoskelet Disord; 2017 Aug; 18(1):337. PubMed ID: 28778219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids.
    Breivik H; Ljosaa TM; Stengaard-Pedersen K; Persson J; Aro H; Villumsen J; Tvinnemose D
    Scand J Pain; 2010 Jul; 1(3):122-141. PubMed ID: 29913983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial.
    Conaghan PG; O'Brien CM; Wilson M; Schofield JP
    Osteoarthritis Cartilage; 2011 Aug; 19(8):930-8. PubMed ID: 21477658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
    Mitra F; Chowdhury S; Shelley M; Williams G
    Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights.
    Norrlid H; Dahm P; Tennvall GR
    Scand J Pain; 2015 Jan; 6(1):24-30. PubMed ID: 29911578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age.
    Likar R; Vadlau EM; Breschan C; Kager I; Korak-Leiter M; Ziervogel G
    Clin J Pain; 2008; 24(6):536-43. PubMed ID: 18574363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial.
    Sittl R; Griessinger N; Likar R
    Clin Ther; 2003 Jan; 25(1):150-68. PubMed ID: 12637117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.
    Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L
    J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
    Griessinger N; Sittl R; Likar R
    Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pain therapy in the elderly:7-day transdermal buprenorphine patch in clinical practice. Results of a non-interventional study].
    Wahle K; Krings D; Schwenke K
    MMW Fortschr Med; 2013 Mar; 155 Suppl 1():25-31. PubMed ID: 23678668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Satisfaction, Adherence and Health-Related Quality of Life with Transdermal Buprenorphine Compared with Oral Opioid Medications in the Usual Care of Osteoarthritis Pain.
    Conaghan PG; Serpell M; McSkimming P; Junor R; Dickerson S
    Patient; 2016 Aug; 9(4):359-71. PubMed ID: 27314487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.
    Plosker GL
    Drugs; 2011 Dec; 71(18):2491-509. PubMed ID: 22141389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose 7-day transdermal buprenorphine in daily clinical practice - perceptions of elderly patients with moderate non-malignant chronic pain.
    Uberall MA; Müller-Schwefe GH
    Curr Med Res Opin; 2012 Oct; 28(10):1585-95. PubMed ID: 22978772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J; Sittl R
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.